Controlled Substances

March 28, 2022 | Controlled Substances, Criminal Justice, Drug Courts, Law Enforcement, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Abuse, Synthetic Drugs

In September 2021, Georgetown University Law Center convened an Opioid Litigation Summit. This convening brought together numerous experts to discuss legal, administrative, and programmatic strategies needed to optimize the impact of proceeds from the opioid litigation. The themes described in this brief emerged from the Summit and can be applied to the opioid litigation as well as future mass tort litigation to address public health crises....

March 3, 2022 | Controlled Substances, Harm Reduction, Innovative Initiatives, Law Enforcement, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Treatments

When Pennsylvania Attorney General Josh Shapiro learned that approximately 15 citizens of the Commonwealth of Pennsylvania die each day from an overdose, he took action. As a result, in May of 2018, he launched the Law Enforcement Treatment Initiative (LETI) to connect individuals suffering with a substance use disorder (SUD) to treatment resources....

March 2, 2022 | Controlled Substances, Criminal Justice, Drug Courts, First Responders, Harm Reduction, Law Enforcement, Model Laws, Public Health, Public Safety, Recovery, Substance Abuse, Treatments

The Model Law Enforcement and Other First Responder Deflection Act, drafted in collaboration with the Police, Treatment, and Community Collaborative (PTACC), encourages the use and establishment of deflection programs on the state level. Specifically, the model act (1) authorizes law enforcement and other first responders to develop and implement collaborative deflection programs that provide proactive policing to assist individuals who are at risk; (2) offers pathways to treatment, recovery services, housing, medication for addiction treatment, whole family services, and other needed supports; (3) requires deflection programs to have certain threshold elements to be eligible to receive grant funding; and (4) requires agencies establishing deflection programs to develop comprehensive memoranda of understanding in conjunction with, and agreed to by, all deflection program partners....

March 2, 2022 | Controlled Substances, Criminal Justice, Drug Courts, Law Enforcement, Opioids, Public Health, Recovery, Reports & Studies, Substance Abuse, Synthetic Drugs

“Stigma” is defined as stereotypes or negative views attributed to a person or groups of people whose characteristics or behaviors are viewed as different from, or inferior to, societal norms. Surveys of public attitudes about various stigmatizing conditions indicate that individuals with a substance use disorder are viewed more negatively than individuals with a mental disorder. This report, released in collaboration with Rulo Strategies LLC, explores efforts to reduce stigma towards individuals with a substance use disorder in public safety and justice settings....

February 16, 2022 | Controlled Substances, Criminal Justice, Fentanyl, Law Enforcement, Opioids, Reports & Studies, Synthetic Drugs, Trafficking

The Commission on Combating Synthetic Opioid Trafficking, established under Section 7221 of the National Defense Authorization Act for Fiscal Year 2020, was charged with examining aspects of the synthetic opioid threat to the United States—specifically, with developing a consensus on a strategic approach to combating the illegal flow of synthetic opioids into the United States. This final report describes items involving the illegal manufacturing and trafficking of synthetic opioids, as well as the deficiencies in countering their production and distribution, and includes action items directed to appropriate executive branch agencies and congressional committees and leadership....

February 8, 2022 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Toolkits, Treatments

The 2022 AMA-Manatt Toolkit builds on a previously published roadmap by providing actionable resources that states can use to take specific actions in six policy areas: (1) Increase access to evidence-based treatments to help patients with a substance use disorder (SUD); (2) Ensure access to addiction medicine, psychiatry, and other trained physicians; (3) Enforce mental health and substance use disorder (SUD) parity laws; (4) Improve access to multidisciplinary, multimodal care for patients with pain; (5) Expand harm reduction efforts to reduce death and disease; and (6) Improve monitoring and evaluation....

December 10, 2021 | Controlled Substances, Criminal Justice, Harm Reduction, Opioids, Prescription Drugs, Public Health, Recovery, Reports & Studies, Substance Abuse, Treatments

The Bloomberg School of Public Health at Johns Hopkins University recently released a three-part report about the multi-district opioid litigation that has been making its way through the court system for many years. Part 1 of the trilogy, focuses on a series of principles governing the use of the settlement funds: (1) spending money to save lives; (2) using evidence to guide spending; (3) investing in youth prevention; (4) focusing on racial equity; and (5) developing a fair and transparent process for deciding where to spend the funding....